ALK and non-small cell lung carcinoma: With extensive research on molecular biology, targeted therapy, particularly epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and anaplastic lymphoma kinase-TKIs showed greater response rates and longer OS than chemotherapy in advanced NSCLC in the last decade, and has been recommended as the first-line treatment by the National Comprehensive Cancer Network (NCCN) guideline [3–9].